Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 20 de 28
Filter
1.
Adv Ther ; 40(9): 3697-3722, 2023 09.
Article in English | MEDLINE | ID: mdl-37436594

ABSTRACT

Desmoid tumors (DT) are rare, locally aggressive, fibroblastic soft-tissue tumors that are characterized by infiltrative growth and can affect organs and adjacent structures, resulting in substantial clinical burden impacting patients' health-related quality of life. Searches of PubMed, Embase, Cochrane, and key conferences were conducted in November 2021 and updated periodically through March 2023 to identify articles describing the burden of DT. Of 651 publications identified, 96 relevant ones were retained. Diagnosis of DT is challenging because of its morphologic heterogeneity and variable clinical presentation. Patients visit multiple healthcare providers, often facing delays in correct diagnosis. The low incidence of DT (estimated 3-5 cases per million person-years) limits disease awareness. Patients with DT experience a high symptom burden: up to 63% of patients experience chronic pain, which leads to sleep disturbance (73% of cases), irritability (46% of cases), and anxiety/depression (15% of cases). Frequently mentioned symptoms are pain, limited function and mobility, fatigue, muscle weakness, and swelling around the tumor. Overall, quality of life in patients with DT is lower than in healthy controls. There is no treatment approved by the US Food and Drug Administration for DT; however, treatment guidelines reference available options, such as active surveillance, surgery, systemic therapy, and locoregional therapy. Choice of active treatment may depend on tumor location, symptoms, and risk of morbidity. The substantial burden of illness of DT is related to difficulties in timely and accurate diagnosis, high symptom burden (pain and functional limitations), and decreased quality of life. There is a high unmet need for treatments that specifically target DT and improve quality of life.


Subject(s)
Fibromatosis, Aggressive , Humans , Fibromatosis, Aggressive/diagnosis , Fibromatosis, Aggressive/therapy , Fibromatosis, Aggressive/pathology , Quality of Life , Pain
2.
J Manag Care Spec Pharm ; 29(5-a Suppl): S2-S11, 2023 May.
Article in English | MEDLINE | ID: mdl-37125931

ABSTRACT

Geographic atrophy (GA) is an advanced form of age-related macular degeneration (AMD), characterized by atrophic lesions that first start in the outer retina and progressively expand to cover the macula and the fovea, the center of the macula, leading to irreversible loss of vision over time. GA is distinct from wet or neovascular AMD (nAMD), the other form of advanced AMD. Neovascular AMD is characterized by new invading leaky blood vessels in the macula that can lead to acute vision loss. GA and nAMD may coexist in the same eye. The underlying pathophysiology of GA is complex and thought to involve chronic inflammation due to overactivation of the complement system that leads to the loss of photoreceptors, retinal pigment epithelium (RPE), and the underlying choriocapillaris. The disappearance of these structures appears as sharply demarcated atrophic lesions that are typical of GA. Researchers have reported about 1 million reported cases of GA in the United States, and about 160,000 cases occur per year. The most important risk factors for GA are increasing age and family history. Diagnosis of GA is usually made by using multimodal imaging techniques. Lesions associated with GA are highly heterogeneous, and the growth rate may differ from patient to patient. Despite the progressive nature of GA, the fovea may be spared until much later in the disease, thereby retaining central vision in patients. With time, atrophic lesions may progressively grow to involve the fovea, thereby severely impairing central vision. Vision loss can happen rapidly once the lesions reach the fovea. However, even without the involvement of the fovea, ongoing vision impairment impacting daily life may be present. Median time from GA not involving the center of the fovea (without subfoveal involvement) to GA with lesion boundary affecting the foveal center (subfoveal involvement) ranges from 1.4 to 2.5 years. GA can greatly impact patients' functioning and quality of life and limit their independence by interfering with activities of daily living, including difficulties with reading, driving, watching television, recognizing faces, and being unable to do household chores. No treatments have been available until intravitreal pegcetacoplan was recently approved by the US Food and Drug Administration for GA secondary to AMD. DISCLOSURES: Dr Bakri serves as a consultant to Apellis Pharmaceuticals, as well as AbbVie, Adverum, Eyepoint, iLumen, Iveric Bio, Genentech, Novartis, Outlook Therapeutics, Pixium, Regeneron, Roche, and Regenxbio. Drs Sharp, Luo, and Sarda are employees of Apellis Pharmaceuticals. Dr Bektas and Ms Khan are employees of RTI Health Solutions. Apellis developed and led the concept design of this publication, review and interpretation, approval, and decision to publish. This research was developed under a research contract between RTI Health Solutions and Apellis Pharmaceuticals and was funded by Apellis Pharmaceuticals. This supplement is to describe the disease of geographic atrophy and was funded by Apellis. Apellis Pharmaceuticals has developed Syfovre (pegcetacoplan), the first and only treatment for geographic atrophy.


Subject(s)
Geographic Atrophy , Wet Macular Degeneration , Humans , Geographic Atrophy/diagnosis , Geographic Atrophy/drug therapy , Geographic Atrophy/etiology , Angiogenesis Inhibitors/therapeutic use , Activities of Daily Living , Quality of Life , Wet Macular Degeneration/drug therapy , Vascular Endothelial Growth Factor A , Visual Acuity , Complement System Proteins/therapeutic use , Pharmaceutical Preparations
3.
Clin Ophthalmol ; 15: 4629-4644, 2021.
Article in English | MEDLINE | ID: mdl-34916775

ABSTRACT

PURPOSE: Geographic atrophy (GA), the advanced form of dry age-related macular degeneration, can result in irreversible blindness over time. We performed a systematic literature review to assess the humanistic and economic burden of GA. METHODS: Predefined search terms were used to identify studies in PubMed, Embase, and Cochrane Library; conference abstracts also were searched. RESULTS: Of 1111 unique studies identified, 25 studies on humanistic burden, 4 on economic burden, and 3 on both humanistic and economic burden of GA were included. Vision-related functioning and health-related quality of life (HRQOL) are poor in patients with GA. HRQOL is commonly measured using the 25-item National Eye Institute Visual Function Questionnaire (NEI VFQ-25); patients with GA have significantly lower composite and subscale scores for near activities, distance activities, dependency, driving, social functioning, mental health, role difficulties, color vision, and peripheral vision than individuals without GA. Driving is a particular concern, and inability to drive affects dependency. Vision-related quality of life (VRQOL) declines as GA progresses. While we identified only 7 reports describing the economic burden of GA, its direct costs may be substantial. In a US study, mean cost to the payer per patient with GA was $11,533 in the year after diagnosis. A multinational study estimated annualized total direct costs of €1772 per patient with GA, mainly driven by diagnostic tests and procedures (€1071). Patients with GA are at increased risk of falls and fractures, potentially increasing direct costs. Only one study evaluated indirect costs, estimating ~$24.4 billion in yearly lost wages among people with severe vision loss due to GA or drusen ≥125 µm. CONCLUSION: GA represents a significant humanistic burden. Evidence on the economic impact of GA is limited; characterizing the economic burden of GA requires further research. Interventions that reduce GA-related disability may improve HRQOL and reduce indirect costs.

4.
J Manag Care Spec Pharm ; 26(12-b Suppl): S8-S14, 2020 Dec.
Article in English | MEDLINE | ID: mdl-33356781

ABSTRACT

Patients with paroxysmal nocturnal hemoglobinuria (PNH) often experience a lengthy path to diagnosis. Fewer than 40% of patients with PNH receive a diagnosis within 12 months of symptom onset, and 24% of all PNH diagnoses can take 5 years or longer. Diagnostic delay is a source of distress and can affect emotional well-being for patients with PNH. In PNH disease management, patients and care providers focus on risk of organ failure and mortality related to disease progression; nonetheless, patients' health-related quality of life (HRQOL) is largely affected by extensive treatment requirements and nonfatal complications of disease, such as fatigue. In particular, thrombosis is associated with significant impairments in physical and social functioning and global health status and significant fatigue. Among patients with anemia who are transfusion dependent, the burden of transfusion is considerable. Transfusion dependence has a negative effect on HRQOL; is associated with risks and complications, including iron overload; and results in lost productivity due to travel times to and time spent at infusion centers. DISCLOSURES: This research was developed under a research contract between RTI Health Solutions and Apellis Pharmaceuticals and was funded by Apellis Pharmaceuticals. Bektas, Copley-Merriman, and Khan are employees of RTI Health Solutions. Sarda is an employee of Apellis Pharmaceuticals. Shammo consults for Apellis Pharmaceuticals.


Subject(s)
Hemoglobinuria, Paroxysmal/psychology , Blood Transfusion/methods , Cost of Illness , Delayed Diagnosis , Disease Progression , Hemoglobinuria, Paroxysmal/diagnosis , Hemoglobinuria, Paroxysmal/therapy , Humans , Quality of Life
5.
J Manag Care Spec Pharm ; 26(12-b Suppl): S3-S8, 2020 Dec.
Article in English | MEDLINE | ID: mdl-33356782

ABSTRACT

The complement system is part of the innate immune response system, which comprises more than 50 distinct plasma and serum proteins that interact to opsonize pathogens (i.e., mark pathogens for destruction) and induce inflammatory responses to fight infection. The role of the complement system is 2-fold: immune surveillance and host defense. Paroxysmal nocturnal hemoglobinuria (PNH) is a rare, chronic, acquired, hematologic disease caused by somatic mutations in the gene PIGA in the hematopoietic stem cells. These stem cells produce abnormal clone blood cells that lack the complement regulatory proteins CD55 and CD59, causing the body to recognize these otherwise healthy red blood cells as damaged. The complement system destroys cells without these protective proteins, resulting in general hemolysis. PNH is characterized by fatigue; hemolytic anemia that can be severe and debilitating; increased lactic dehydrogenase level, reticulocyte count, and bilirubin level; propensity for thrombotic events; and renal dysfunction. Epidemiologic data, while sparse, suggest that an estimated 5,000-6,000 individuals in the United States are affected by PNH. If left untreated, PNH has a 10-year mortality rate of 29%, although the natural history of this disease has been recently altered by the introduction of complement inhibitors for the treatment of PNH. DISCLOSURES: This research was developed under a research contract between RTI Health Solutions and Apellis Pharmaceuticals and was funded by Apellis Pharmaceuticals. Bektas, Copley-Merriman, and Khan are employees of RTI Health Solutions. Sarda is an employee of Apellis Pharmaceuticals. Shammo consults for Apellis Pharmaceuticals.


Subject(s)
Complement System Proteins , Hemoglobinuria, Paroxysmal/physiopathology , Animals , Hemoglobinuria, Paroxysmal/therapy , Hemolysis , Humans , Immunity, Innate
6.
J Manag Care Spec Pharm ; 26(12-b Suppl): S14-S20, 2020 Dec.
Article in English | MEDLINE | ID: mdl-33356783

ABSTRACT

The current standard of care for paroxysmal nocturnal hemoglobinuria (PNH) are the C5 inhibitors eculizumab and ravulizumab, both monoclonal antibodies designed to target the complement protein C5, thereby preventing its cleavage and the formation of the terminal attack complex. C5 inhibitors have yielded substantial improvements in the treatment of PNH and changed the mortality and morbidity, as well as health-related quality of life of patients with the disease. These treatments target underlying intravascular hemolysis; however, they do not address extravascular hemolysis, resulting in incomplete response and remaining symptoms in some patients. Therefore, despite treatment with a C5 inhibitor, some patients still experience anemia with associated fatigue, transfusion needs, and impaired health-related quality of life. DISCLOSURES: This research was developed under a research contract between RTI Health Solutions and Apellis Pharmaceuticals and was funded by Apellis Pharmaceuticals. Bektas, Copley-Merriman, and Khan are employees of RTI Health Solutions. Sarda is an employee of Apellis Pharmaceuticals. Shammo consults for Apellis Pharmaceuticals.


Subject(s)
Hemoglobinuria, Paroxysmal/drug therapy , Anemia/etiology , Antibodies, Monoclonal, Humanized , Complement C5/antagonists & inhibitors , Health Services Needs and Demand , Hemoglobinuria, Paroxysmal/complications , Hemoglobinuria, Paroxysmal/mortality , Hemolysis , Humans , Quality of Life
7.
J Biol Chem ; 289(9): 5462-6, 2014 Feb 28.
Article in English | MEDLINE | ID: mdl-24398691

ABSTRACT

Non-healing wounds are a significant source of morbidity. This is particularly true for diabetic patients, who tend to develop chronic skin wounds. O-GlcNAc modification of serine and threonine residues is a common regulatory post-translational modification analogous to protein phosphorylation; increased intracellular protein O-GlcNAc modification has been observed in diabetic and hyperglycemic states. Two intracellular enzymes, UDP-N-acetylglucosamine-polypeptide ß-N-acetylglucosaminyl transferase (OGT) and O-GlcNAc-selective N-acetyl-ß-D-glucosaminidase (OGA), mediate addition and removal, respectively, of N-acetylglucosamine (GlcNAc) from intracellular protein substrates. Alterations in O-GlcNAc modification of intracellular proteins is linked to diabetes, and the increased levels of protein O-GlcNAc modification observed in diabetic tissues may in part explain some of the observed underlying pathophysiology that contributes to delayed wound healing. We have previously shown that increasing protein O-GlcNAc modification by overexpression of OGT in murine keratinocytes results in elevated protein O-GlcNAc modification and a hyperadhesive phenotype. This study was undertaken to explore the hypothesis that increased O-GlcNAc modification of cellular proteins in diabetic skin could contribute to the delayed wound healing observed in patients with diabetic skin ulcers. In the present study, we show that human keratinocytes cultured under hyperglycemic conditions display increased levels of O-GlcNAc modification as well as a delay in the rate of wound closure in vitro. We further show that specific knockdown of OGT by RNA interference (RNAi) reverses this effect, thereby opening up the opportunity for OGT-targeted therapies to promote wound healing in diabetic patients.


Subject(s)
Diabetes Complications/enzymology , Diabetes Complications/therapy , N-Acetylglucosaminyltransferases/metabolism , Skin/enzymology , Wound Healing , Wounds and Injuries/enzymology , Wounds and Injuries/therapy , Acetylglucosamine/genetics , Acetylglucosamine/metabolism , Animals , Cell Line , Diabetes Complications/genetics , Diabetes Complications/pathology , Gene Knockdown Techniques , Glycosylation , Humans , Keratinocytes/enzymology , Keratinocytes/pathology , Mice , N-Acetylglucosaminyltransferases/antagonists & inhibitors , N-Acetylglucosaminyltransferases/genetics , Protein Modification, Translational/genetics , RNA Interference , Skin/pathology , Wounds and Injuries/genetics , Wounds and Injuries/pathology
8.
J Biol Chem ; 288(13): 9447-56, 2013 Mar 29.
Article in English | MEDLINE | ID: mdl-23404504

ABSTRACT

The pemphigus family of autoimmune bullous disorders is characterized by autoantibody binding to desmoglein 1 and/or 3 (dsg1/dsg3). In this study we show that EGF receptor (EGFR) is activated following pemphigus vulgaris (PV) IgG treatment of primary human keratinocytes and that EGFR activation is downstream of p38 mitogen-activated protein kinase (p38). Inhibition of EGFR blocked PV IgG-triggered dsg3 endocytosis, keratin intermediate filament retraction, and loss of cell-cell adhesion in vitro. Significantly, inhibiting EGFR prevented PV IgG-induced blister formation in the passive transfer mouse model of pemphigus. These data demonstrate cross-talk between dsg3 and EGFR, that this cross-talk is regulated by p38, and that EGFR is a potential therapeutic target for pemphigus. Small-molecule inhibitors and monoclonal antibodies directed against EGFR are currently used to treat several types of solid tumors. This study provides the experimental rationale for investigating the use of EGFR inhibitors in pemphigus.


Subject(s)
Acantholysis/metabolism , ErbB Receptors/metabolism , Gene Expression Regulation , Immunoglobulin G/metabolism , Pemphigus/metabolism , Animals , Animals, Newborn , Cell Adhesion , Cells, Cultured , Desmogleins/metabolism , Desmosomes/metabolism , Detergents/pharmacology , Disease Models, Animal , Female , Humans , Immunoglobulin G/chemistry , Keratinocytes/cytology , Keratins/metabolism , Male , Mice , Mice, Inbred C57BL , Microscopy, Confocal/methods , Microscopy, Fluorescence/methods , RNA, Small Interfering/metabolism , Signal Transduction , p38 Mitogen-Activated Protein Kinases/metabolism
9.
J Biol Chem ; 286(9): 7348-58, 2011 Mar 04.
Article in English | MEDLINE | ID: mdl-21173151

ABSTRACT

Sphingosine-1-phosphate (S1P) lyase catalyzes the degradation of S1P, a potent signaling lysosphingolipid. Mice with an inactive S1P lyase gene are impaired in the capacity to degrade S1P, resulting in highly elevated S1P levels. These S1P lyase-deficient mice have low numbers of lymphocytes and high numbers of neutrophils in their blood. We found that the S1P lyase-deficient mice exhibited features of an inflammatory response including elevated levels of pro-inflammatory cytokines and an increased expression of genes in liver associated with an acute-phase response. However, the recruitment of their neutrophils into inflamed tissues was impaired and their neutrophils were defective in migration to chemotactic stimulus. The IL-23/IL-17/granulocyte-colony stimulating factor (G-CSF) cytokine-controlled loop regulating neutrophil homeostasis, which is dependent on neutrophil trafficking to tissues, was disturbed in S1P lyase-deficient mice. Deletion of the S1P4 receptor partially decreased the neutrophilia and inflammation in S1P lyase-deficient mice, implicating S1P receptor signaling in the phenotype. Thus, a genetic block in S1P degradation elicits a pro-inflammatory response but impairs neutrophil migration from blood into tissues.


Subject(s)
Aldehyde-Lyases , Cell Movement/immunology , Lysophospholipids/metabolism , Neutrophils , Signal Transduction/immunology , Sphingosine/analogs & derivatives , Acute-Phase Proteins/immunology , Aldehyde-Lyases/genetics , Aldehyde-Lyases/immunology , Aldehyde-Lyases/metabolism , Animals , Biomarkers/metabolism , Cell Adhesion Molecules/immunology , Cell Adhesion Molecules/metabolism , Hematopoiesis/immunology , Inflammation/immunology , Inflammation/metabolism , Lysophospholipids/immunology , Mice , Mice, Knockout , Neutrophils/cytology , Neutrophils/enzymology , Neutrophils/immunology , Sphingosine/immunology , Sphingosine/metabolism
10.
J Biomed Res ; 25(4): 227-36, 2011 Jul.
Article in English | MEDLINE | ID: mdl-23554695

ABSTRACT

Post-translational protein modification, including phosphorylation, is generally quick and reversible, facilitating rapid biologic adjustments to altered cellular physiologic demands. In addition to protein phosphorylation, other post-translational modifications have been identified. Intracellular protein O-glycosylation, the addition of the simple sugar O-linked N-acetylglucosamine (O-GlcNAc) to serine/threonine residues, is a relatively recently identified post-translational modification that has added to the complexity by which protein function is regulated. Two intracellular enzymes, O-GlcNAc transferase and O-GlcNAcase, catalyze the addition and removal, respectively, of O-GlcNAc to serine and threonine side-chain hydroxyl groups. Numerous proteins, including enzymes, transcription factors, receptors and structural proteins have been shown to be modified by intracellular O-glycosylation. In this review, the mechanism and relevance of O-GlcNAc protein modification are discussed in the context of cell adhesion and several representative diseases.

11.
Dermatol Res Pract ; 2010: 456841, 2010.
Article in English | MEDLINE | ID: mdl-20631907

ABSTRACT

Pemphigus is a group of human autoimmune blistering diseases of the skin in which autoantibodies to desmosome cadherins induce loss of cell-cell adhesion (acantholysis). In addition to steric hindrance and activation of intracellular signaling, apoptosis has been suggested to contribute to the mechanism by which pathogenic IgG induces acantholysis. We review the current literature examining the role of apoptosis in pemphigus. Current data suggest that apoptosis is not required for blister induction, but that activation of proapoptotic proteins, including caspase cysteine proteinases, may sensitize cells to the acantholytic effects of pemphigus IgG.

12.
J Biol Chem ; 285(14): 10880-9, 2010 Apr 02.
Article in English | MEDLINE | ID: mdl-20097939

ABSTRACT

The cleavage of sphingoid base phosphates by sphingosine-1-phosphate (S1P) lyase to produce phosphoethanolamine and a fatty aldehyde is the final degradative step in the sphingolipid metabolic pathway. We have studied mice with an inactive S1P lyase gene and have found that, in addition to the expected increase of sphingoid base phosphates, other sphingolipids (including sphingosine, ceramide, and sphingomyelin) were substantially elevated in the serum and/or liver of these mice. This latter increase is consistent with a reutilization of the sphingosine backbone for sphingolipid synthesis due to its inability to exit the sphingolipid metabolic pathway. Furthermore, the S1P lyase deficiency resulted in changes in the levels of serum and liver lipids not directly within the sphingolipid pathway, including phospholipids, triacyglycerol, diacylglycerol, and cholesterol. Even though lipids in serum and lipid storage were elevated in liver, adiposity was reduced in the S1P lyase-deficient mice. Microarray analysis of lipid metabolism genes in liver showed that the S1P lyase deficiency caused widespread changes in their expression pattern, with a significant increase in the expression of PPARgamma, a master transcriptional regulator of lipid metabolism. However, the mRNA expression of the genes encoding the sphingosine kinases and S1P phosphatases, which directly control the levels of S1P, were not significantly changed in liver of the S1P lyase-deficient mice. These results demonstrate that S1P lyase is a key regulator of the levels of multiple sphingolipid substrates and reveal functional links between the sphingolipid metabolic pathway and other lipid metabolic pathways that may be mediated by shared lipid substrates and changes in gene expression programs. The disturbance of lipid homeostasis by altered sphingolipid levels may be relevant to metabolic diseases.


Subject(s)
Aldehyde-Lyases/physiology , Biomarkers/metabolism , Lipids/analysis , Liver/metabolism , Animals , Blotting, Western , Female , Gene Expression Profiling , Homeostasis , Immunoenzyme Techniques , Lipid Metabolism , Liver/cytology , Lysophospholipids/metabolism , Male , Mice , Mice, Knockout , Oligonucleotide Array Sequence Analysis , RNA, Messenger/genetics , RNA, Messenger/metabolism , Reverse Transcriptase Polymerase Chain Reaction , Signal Transduction , Sphingosine/analogs & derivatives , Sphingosine/metabolism
13.
J Biol Chem ; 285(12): 8936-41, 2010 Mar 19.
Article in English | MEDLINE | ID: mdl-20093368

ABSTRACT

Pemphigus vulgaris (PV) is an autoimmune blistering disease in which antibodies against the desmosomal cadherin, DSG3 (desmoglein-3), cause acantholysis. It has become increasingly clear that loss of cell-cell adhesion in PV is a complex and active process involving multiple signaling events such as activation of p38MAPK. It has also been demonstrated that incubating keratinocytes with PV IgG causes a redistribution of DSG3 from the cell surface to endosomes, which target these proteins for degradation. This study was undertaken to determine the relationship between p38MAPK and DSG3 endocytosis in pemphigus. In this work, we confirm that PV IgG causes internalization of cell-surface DSG3 into endosomes (as early as 4 h), which are then depleted from both detergent-soluble and detergent-insoluble pools. Cell-surface DSG3 internalization and depletion from both the detergent-soluble and detergent-insoluble fractions were blocked by the p38MAPK inhibitor SB202190. These data suggest that p38MAPK is capable of regulating PV IgG-mediated DSG3 internalization and that previously isolated mechanistic observations may be linked to a common pathway by which pemphigus autoantibodies lead to acantholysis.


Subject(s)
Desmoglein 3/metabolism , Gene Expression Regulation, Enzymologic , Pemphigus/metabolism , p38 Mitogen-Activated Protein Kinases/metabolism , Autoantibodies/chemistry , Biotinylation , Cell Membrane/metabolism , Detergents/pharmacology , Endocytosis , Endosomes/metabolism , Humans , Immunoglobulin G/chemistry , Keratinocytes/cytology , Microscopy, Confocal/methods , Signal Transduction
14.
J Invest Dermatol ; 130(1): 10-2, 2010 Jan.
Article in English | MEDLINE | ID: mdl-20010861

ABSTRACT

In this issue of the Journal, Robitaille and colleagues present data supporting a role for the small heat shock protein (HSP) 27 in keratinocyte terminal differentiation. This adds to the growing literature implicating HSP27 as a regulator of biologic function beyond thermal stress response.


Subject(s)
HSP27 Heat-Shock Proteins/physiology , Keratinocytes/cytology , Keratinocytes/physiology , Animals , Cell Differentiation/physiology , Humans
15.
Cancer Chemother Pharmacol ; 64(5): 1053-8, 2009 Oct.
Article in English | MEDLINE | ID: mdl-19597728

ABSTRACT

PURPOSE: Sphingosine kinase is an oncogene that is up-regulated in several solid tumors. The product of the sphingosine kinase activity, sphingosine-1-phosphate is a potent mitogen involved in diverse cell processes such as cell survival and migration. Current standard therapy in the treatment of glioblastoma multiforme (GBM) is a combination of surgery, radiation, and chemotherapy using the drug temozolomide (TMZ). However, virtually all tumors become resistant to TMZ. Therefore, new drug targets are necessary. In this study, we investigated whether inhibiting sphingosine kinase could induce cell death in TMZ-resistant GBM cells. METHODS: To study TMZ resistance in vitro, we have generated TMZ-resistant cell lines from established GBM cells. We used a potent inhibitor of sphingosine kinase to study its effect on colony formation and cell growth in GBM cells with a limited dilution and WST assay. Moreover, cell death was determined by measuring caspase-3 activity using flow cytometry. RESULTS: A sphingosine kinase inhibitor reduced cell colony formation and activated caspase-3 in both TMZ-sensitive and resistant GBM cells. CONCLUSION: Addition of a sphingosine kinase inhibitor to the standard chemotherapy regimen against GBM may be beneficial.


Subject(s)
Aniline Compounds/pharmacology , Antineoplastic Agents, Alkylating/pharmacology , Dacarbazine/analogs & derivatives , Enzyme Inhibitors/pharmacology , Glioblastoma/drug therapy , Phosphotransferases (Alcohol Group Acceptor)/antagonists & inhibitors , Thiazoles/pharmacology , Apoptosis/drug effects , Caspase 3/metabolism , Cell Death/drug effects , Cell Line, Tumor , Cell Proliferation/drug effects , Dacarbazine/pharmacology , Drug Resistance, Neoplasm , Flow Cytometry , Glioblastoma/pathology , Humans , Indicator Dilution Techniques , Oligonucleotide Array Sequence Analysis , Reverse Transcriptase Polymerase Chain Reaction , Temozolomide
16.
J Invest Dermatol ; 129(7): 1606-8, 2009 Jul.
Article in English | MEDLINE | ID: mdl-19521407

ABSTRACT

In this issue, Nguyen et al. demonstrate a role for Perp in desmosome assembly and trafficking and pemphigus IgG-mediated acantholysis, providing further insights into the complexity of desmosome structure and regulation.


Subject(s)
Desmosomes/metabolism , Desmosomes/pathology , Membrane Proteins/metabolism , Pemphigus/metabolism , Pemphigus/pathology , Genes, Tumor Suppressor , Humans , Protein Transport/physiology
17.
Hum Mol Genet ; 17(15): 2257-64, 2008 Aug 01.
Article in English | MEDLINE | ID: mdl-18424450

ABSTRACT

Sphingosine-1-phosphate (S1P) is a lipid-signaling molecule produced by sphingosine kinase in response to a wide number of stimuli. By acting through a family of widely expressed G protein-coupled receptors, S1P regulates diverse physiological processes. Here we examined the role of S1P signaling in neurodegeneration using a mouse model of Sandhoff disease, a prototypical neuronopathic lysosomal storage disorder. When sphingosine kinase 1 (Sphk1) was deleted in Sandhoff disease mice, a milder disease course occurred, with decreased proliferation of glial cells and less-pronounced astrogliosis. A similar result of milder disease course and reduced astroglial proliferation was obtained by deletion of the gene for the S1P(3) receptor, a G protein-coupled receptor enriched in astrocytes. Our studies demonstrate a functional role of S1P synthesis and receptor expression in astrocyte proliferation leading to astrogliosis during the terminal stages of neurodegeneration in Sandhoff disease mice. Because astrocyte responses are involved in many types of neurodegeneration, the Sphk1/S1P receptor signaling axis may be generally important during the pathogenesis of neurodegenerative diseases.


Subject(s)
Astrocytes/pathology , Gliosis/genetics , Phosphotransferases (Alcohol Group Acceptor)/physiology , Receptors, Lysosphingolipid/physiology , Sandhoff Disease/genetics , Sandhoff Disease/pathology , Animals , Astrocytes/metabolism , Cell Proliferation , Disease Models, Animal , Gene Deletion , Lysophospholipids/biosynthesis , Male , Mice , Mice, Mutant Strains , Phosphotransferases (Alcohol Group Acceptor)/genetics , Receptors, Lysosphingolipid/genetics , Signal Transduction , Sphingosine/analogs & derivatives , Sphingosine/biosynthesis , Sphingosine-1-Phosphate Receptors , Spinal Cord/metabolism , Spinal Cord/pathology
18.
J Cell Biol ; 169(5): 801-11, 2005 Jun 06.
Article in English | MEDLINE | ID: mdl-15939762

ABSTRACT

The bioactive phospholipids, lysophosphatidic acid (LPA) and phosphatidic acid (PA), regulate pivotal processes related to the pathogenesis of cancer. Here, we report characterization of a novel lipid kinase, designated acylglycerol kinase (AGK), that phosphorylates monoacylglycerol and diacylglycerol to form LPA and PA, respectively. Confocal microscopy and subcellular fractionation suggest that AGK is localized to the mitochondria. AGK expression was up-regulated in prostate cancers compared with normal prostate tissues from the same patient. Expression of AGK in PC-3 prostate cancer cells markedly increased formation and secretion of LPA. This increase resulted in concomitant transactivation of the EGF receptor and sustained activation of extracellular signal related kinase (ERK) 1/2, culminating in enhanced cell proliferation. AGK expression also increased migratory responses. Conversely, down-regulating expression of endogenous AGK inhibited EGF- but not LPA-induced ERK1/2 activation and progression through the S phase of the cell cycle. Hence, AGK can amplify EGF signaling pathways and may play an important role in the pathophysiology of prostate cancer.


Subject(s)
Carcinoma/enzymology , ErbB Receptors/metabolism , Lysophospholipids/biosynthesis , Phosphotransferases (Alcohol Group Acceptor)/genetics , Phosphotransferases (Alcohol Group Acceptor)/metabolism , Prostatic Neoplasms/enzymology , Animals , Carcinoma/genetics , Cell Cycle Proteins/metabolism , Cell Line, Tumor , Cell Proliferation , Diglycerides/metabolism , Down-Regulation/physiology , Glycerides/metabolism , Humans , Male , Mice , Mitochondria/enzymology , Mitogen-Activated Protein Kinase 3/metabolism , NIH 3T3 Cells , Phosphatidic Acids/biosynthesis , Phosphotransferases (Alcohol Group Acceptor)/isolation & purification , Prostatic Neoplasms/genetics , Rats , S Phase/physiology , Transcriptional Activation/physiology , Up-Regulation/physiology
19.
Mol Cell Biol ; 25(10): 4237-49, 2005 May.
Article in English | MEDLINE | ID: mdl-15870293

ABSTRACT

Sphingosine-1-phosphate (S1P), a bioactive sphingolipid metabolite, is the ligand for five specific G protein-coupled receptors, named S1P(1) to S1P(5). In this study, we found that cross-communication between platelet-derived growth factor receptor and S1P(2) serves as a negative damper of PDGF functions. Deletion of the S1P(2) receptor dramatically increased migration of mouse embryonic fibroblasts toward S1P, serum, and PDGF but not fibronectin. This enhanced migration was dependent on expression of S1P(1) and sphingosine kinase 1 (SphK1), the enzyme that produces S1P, as revealed by downregulation of their expression with antisense RNA and small interfering RNA, respectively. Although S1P(2) deletion had no significant effect on tyrosine phosphorylation of the PDGF receptors or activation of extracellular signal-regulated kinase 1/2 or Akt induced by PDGF, it reduced sustained PDGF-dependent p38 phosphorylation and markedly enhanced Rac activation. Surprisingly, S1P(2)-null cells not only exhibited enhanced proliferation but also markedly increased SphK1 expression and activity. Conversely, reintroduction of S1P(2) reduced DNA synthesis and expression of SphK1. Thus, S1P(2) serves as a negative regulator of PDGF-induced migration and proliferation as well as SphK1 expression. Our results suggest that a complex interplay between PDGFR and S1P receptors determines their functions.


Subject(s)
Cell Movement/drug effects , Platelet-Derived Growth Factor/pharmacology , Receptors, Lysosphingolipid/metabolism , Animals , Cell Membrane Structures/drug effects , Cell Proliferation/drug effects , Cells, Cultured , Chemotaxis/drug effects , Enzyme Activation/drug effects , Female , Fibroblasts/cytology , Fibroblasts/drug effects , Fibroblasts/enzymology , Fibroblasts/metabolism , Gene Deletion , Gene Expression , Male , Mice , Models, Biological , Phosphotransferases (Alcohol Group Acceptor)/antagonists & inhibitors , Phosphotransferases (Alcohol Group Acceptor)/metabolism , Receptors, Lysosphingolipid/deficiency , Receptors, Lysosphingolipid/genetics , rac GTP-Binding Proteins/metabolism
20.
Blood ; 105(12): 4736-42, 2005 Jun 15.
Article in English | MEDLINE | ID: mdl-15741218

ABSTRACT

Mast cells play a central role in inflammatory and immediate-type allergic reactions by secreting a variety of biologically active substances, including sphingosine-1 phosphate (S1P). Sphingosine kinase 1 (SphK1) and formation of S1P, which leads to transactivation of S1P receptors and their downstream signaling pathways, regulates mast-cell functions initiated by cross-linking of the high-affinity immunoglobulin E (IgE) receptor FcepsilonRI. Surprisingly, overexpression of SphK1 in rat basophilic leukemia (RBL)-2H3 mast cells impaired degranulation as well as migration toward antigen. These effects were reversed by serum withdrawal, yet the increased formation and secretion of S1P were the same as in the presence of serum. Nonetheless, serum increased localization of SphK1 at the plasma membrane. This restricted formation of S1P induced internalization and desensitization of S1P receptors on the surface of mast cells as determined by confocal immunofluorescence microscopy, aberrant S1P receptor signaling, and lack of S1P receptor coupling to G proteins. Serum starvation, which significantly reduced membrane-associated SphK1 activity, restored S1P receptor functions. Our results have important implications for mast-cell migration and degranulation as well as for the biologic functions of the S1P receptors on cells that are circulating in the bloodstream.


Subject(s)
Mast Cells/metabolism , Phosphotransferases (Alcohol Group Acceptor)/biosynthesis , Phosphotransferases (Alcohol Group Acceptor)/chemistry , Receptors, Lysosphingolipid/metabolism , Animals , Blotting, Western , Calcium/metabolism , Cell Line, Tumor , Cell Membrane/metabolism , Cell Movement , Chemotaxis , Cross-Linking Reagents/pharmacology , Culture Media, Serum-Free/pharmacology , Down-Regulation , GTP-Binding Protein alpha Subunit, Gi2 , GTP-Binding Protein alpha Subunits, Gi-Go/metabolism , GTP-Binding Protein alpha Subunits, Gq-G11/metabolism , Guanosine 5'-O-(3-Thiotriphosphate)/metabolism , Immunoglobulin E/chemistry , Inflammation , Ligands , Microscopy, Confocal , Microscopy, Fluorescence , Mitogen-Activated Protein Kinase 1/metabolism , Mitogen-Activated Protein Kinase 3/metabolism , Phenotype , Phosphorylation , Phosphotransferases (Alcohol Group Acceptor)/metabolism , Protein Transport , Proto-Oncogene Proteins/metabolism , Rats , Receptors, IgE/chemistry , Signal Transduction , Time Factors , Transfection , p38 Mitogen-Activated Protein Kinases/metabolism
SELECTION OF CITATIONS
SEARCH DETAIL
...